Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024 Composition of matter patent application filed on ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
The transition from preclinical development to clinical trials is a critical, yet high-risk stage in drug development, with approximately 89% of drugs failing to progress through all phases of ...
Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, which shows promising tumor ...
(MENAFN- EIN Presswire) EINPresswire/ -- The global preclinical antibody development market is entering a decade of high-velocity growth, with its valuation expected to rise from USD 4.0 billion in ...
OXFORD, England, 07 January 2026 /PRNewswire/ -- Nucleome Therapeutics ('Nucleome' or 'the Company'), a company tackling the molecular causes of inflammatory diseases through a breakthrough approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results